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Abstract
Vascular endothelial growth factor (VEGF) is a major regulator in retinal and choroidal angiogenesis, which are common causes
of blindness in all age groups. Recently anti-VEGF treatment using anti-VEGF antibody has revolutionarily improved the visual
outcome in patientswithvaso-proliferativeretinopathies.Herein, wedemonstrated thatbevacizumabasananti-VEGF antibody
could inhibitdifferentiation ofretinoblastomacellswithout affectiontocellularviability,whichwould bemediated via blockade
of extracellular signal-regulated kinase (ERK) 1/2 activation. The retinoblastoma cells expressed VEGFR-2 as well as TrkA which is
a neurotrophin receptor associated with differentiation of retinoblastoma cells. TrkA in retinoblastoma cells was activated with
VEGF treatment. Interestingly even in the concentration of no cellular death, bevascizumab significantly attenuated the neurite
formation ofdifferentiated retinoblastomacells, which was accompaniedbyinhibitionof neurofilamentand shank2expression.
Furthermore, bevacizumab inhibited differentiation of retinoblastoma cells by blockade of ERK 1/2 activation. Therefore, based
on that the differentiated retinoblastoma cells are mostly photoreceptors, our results suggest that anti-VEGF therapies would
affect to the maintenance or function of photoreceptors in mature retina.
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Introduction
As originally discovered as an endothelial-specific growth factor
[1], vascular endothelial growth factor (VEGF) plays a critical role
in physiological and pathological angiogenesis [2]. Interestingly,
VEGF generated from the nervous system has been documented
to function in neurons as well as endothelial cells [3]. VEGF seems
to share common molecular triggers and signaling pathways in
neurons and endothelial cells of the nervous system as our previous
suggestion [4,5]. Actually, the neurotrophic and neuroprotective
effect of VEGF could be mediated through its tyrosine kinase
receptor, VEGFR-2 which is widely expressed in neurons and glias
[6]. With recent observations to unravel the direct effect of VEGF
on neurons and glias, VEGF appears to be essential for neuronal
development and survival in physiological and pathological
conditions [7].
Retinal and choroidal neovascularization are common causes of
blindness in all age groups - retinopathy of prematurity (ROP) is
for children, diabetic retinopathy (DR) for young adults and age-
related macular degeneration (AMD) for elderly [8]. Although
other angiogenic factors could contribute to pathological angio-
genesis in the eye, VEGF is a major regulator in retinal and
choroidal angiogenesis [9]. With recent development of anti-
VEGF therapy using anti-VEGF antibody, the visual outcome in
patients with retinal and choroidal vascular diseases has been
revolutionarily improved [10].
Bevacizumab is a full-length humanized monoclonal antibody
to bind to all isoforms of VEGF-A, which was approved by the US
Food and Drug Administration for metastatic colorectal cancer in
combination with an intravenous 5-fluorouracil based regimen
[11]. Without an approval for intraocular use of bevacizumab, its
application has been progressively expanded based on empirical
evidence in clinics [12,13]. Now, bevacizumab is a promising
therapeutic option targeting to VEGF-mediated vasoproliferative
diseases in the retina [14]. However, based on the neurotrophic
and neuroprotective effect of VEGF, concerns have been raised
about neuronal toxicity in the retina following intravitreal injection
of bevacizumab. Although consecutive reports showed little toxic
effect of intravitral bevacizumab on the retina including ganglion
cell, retinal neuron, and retinal pigment epithelial cell [14–17], a
few reports demonstrated that intravitreal bevacizumab could
induce retinal toxicity [18,19]. Therefore, regardless of widespread
use of bevacizumab, some issues for its biocompatibility and safety
remains to be addressed.
In current study, we demonstrated that bevacizumab could
inhibit differentiation of retinoblastoma cells under the concentra-
tion never affecting to cellular viability. The retinoblastoma cells
expressed VEGFR-2 as well as TrkA which is a neurotrophin
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TrkA in retinoblastoma cells was activated with VEGF treatment.
Interestingly even in the concentration of no cellular death,
bevascizumab significantly attenuated the neurite formation of
differentiated retinoblastoma cells, which was accompanied by
inhibitionof neurofilament and shank2expression [21]. In addition,
we showed that bevacizumab inhibits the differentiation of
retinoblastoma cells by blockade of extracellular signal-regulated
kinase (ERK) 1/2 activation. Taken together, it should be carefully
concerned that bevacizumab treatment could attenuate differenti-
ation of retinal neurons though not induces cell death.
Materials and Methods
Cell Culture
Human retinoblastoma cell lines, Y79 and SNUOT-Rb1,
established by our group [22], and a human colorectal cancer cell
line, SW480, were maintained in RPMI 1640 medium (Welgene
Inc., Seoul, Korea) supplemented with 10% fetal bovine serum
(Gibco BRL, Rockville, MD, USA) and 1% antibiotic-antimycotic
solution (Invitrogen, Carlsbad, CA, USA) at 37uC in a moist
atmosphere of 95% air and 5% CO2. The medium was changed
every third day. Cultured tumor cells were observed daily under a
phase-contrast microscope (Carl Zeiss, Chester, VA, USA). If
needed, VEGF (10 ng/ml, Sigma, St. Louis, MO, USA) treatment
was carried out. To induce the differentiation of retinoblastoma
cells, 0.1% bovine serum albumin (BSA, Sigma-Aldrich, St Louis,
MO, USA) supplied into the culture media up to 48 hours.
Cell Viability Assay
Cell viability was determined by using a 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. As our recent
report [17], SNUOT-Rb1 (1610
4 cells) was plated in 96-well
culture plates, and then treated with 0.1 to 10 mg/ml bevacizumab
for 48 hours. The medium was then replaced with fresh medium
containing 0.5 mg/ml MTT for 4 h. After incubation, the medium
was carefully removed from the plate, and dimethyl sulfoxide was
added to solubilize formazan produced from MTT by the viable
cells. Absorbance was measured at 540 nm using a microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
Measurement of Neurite Length in Differentiated
Retinoblastoma Cells
As our recent report [23], neurite length in differentiated
retinoblastoma cells was measured by manual tracing of neurite
outgrowths in each cell. 15 to 20 retinoblastoma cells were
evaluated in randomly selected fields at a magnification of 6400
and photographed with a digital camera (DXC 930 P, Sony,
Tokyo, Japan) under an inverted microscope (Axiovert 200M,
Carl Zeiss). For analysis, differentiated retinoblastoma cells were
selected randomly and neurites were traced manually. Neurite
length was measured from an arbitrary round line connecting
edges of non-spiny cell membrane to the distal tip of the neurite.
Every neurite was traced by a series of straight lines; each neurite
can be mathematically described as a series of straight lines leading
from the edge to the neurite tip. The length of each of these lines
was determined by the curvatures of the neurite such that the line
always overlaid the neurite. Accumulation of the straight line
segments results in a polygon equivalent to the neurite length.
Western Blot Analysis
Cells were harvested, washed with ice-cold phosphate buffer
solution, and lysed with buffer containing 50 mM of Tris–HCl
(pH 7.4), 150 mM of NaCl, 1% Nonidet P40, 2 mM of sodium
orthovanadate, and a protease inhibitor cocktail (Roche). An equal
amount (15 mg) of the samples was separated on sodium dodecylsul-
fate-polyacrylamide gel and then transferred onto nitrocellulosefilters
(Bio-Rad Laboratories, Hercules, CA, USA). The membranes were
immunoblotted with primary antibodies against VEGFR-2 (1:1000,
Santa-Cruz Biotechnology, Santa Cruz, CA, USA), phospho-TrkA
(1:1000, Santa-Cruz Biotechnology, Santa-Cruz, CA, USA), TrkA
(1:1000, Santa-Cruz Biotechnology, Santa-Cruz, CA, USA), neuro-
filament (1:1000, Chemicon, Temecula, CA, USA), shank 2 (1:1000,
Santa-Cruz Biotechnology, Santa Cruz, CA, USA), phospho-ERK
1/2 (1:1000, Cell Signaling Technology, Beverly, MA, USA), ERK
1/2 (1:1000, Cell Signaling Technology), phospho-Akt (1:1000, Cell
Signaling Technology), and Akt (1:1000, Cell Signaling Technology).
To ensure the equal loading of protein in each lane, the blots were
stripped and reprobed with an antibody against b-actin.
Immunocytochemistry
SNUOT-Rb1 was grown and seeded on Deckglaser coverslips
(Carolina Biological, Burlington, NC, USA). Cells were fixed in 4%
paraformaldehyde for over-night at 4uC. The primary antibodies
against neurofilament (1:100, Chemicon, Temecula, CA, USA) and
shank2 (1:100, Santa-Cruz Biotechnology, Santa Cruz, CA, USA)
were diluted in PBS and added to the specimen followed by
incubation for over-night at room temperature. Alexa Fluor 546
donkey anti-goat IgG (1:400, Molecular probes, Eugene, OR,
USA), Alexa Fluor 488 donkey anti-rabbit IgG (1:400, Molecular
probes, Eugene, OR, USA) were used as secondary antibodies. The
nuclei were stained with 49, 6-diamidino-2-phenolindole (DAPI,
Sigma-Aldrich Co., St. Louis, MO, USA). The slides were mounted
with Faramount Aqueous mounting medium (DAKO, Glostrup,
Denmark) and observed under fluorescence microscope (Axio
observer, Carl Zeiss, Chester, VA, USA).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis
Total RNA from cells was isolated using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. First-stranded cDNA was synthesized with 3 mge a c ho f
DNA-free total RNA and oligo-(dT) 16 primer by Moloney murine
leukemia virus reverse transcriptase (Promega, Madison, WI, USA).
Equal amounts of cDNA were subsequently amplified by PCR in a
50-mL reaction volume containing 16 PCR buffer; 200 mMo f
dNTPs; 10 mM of specific primer for neurofilament (59-AAGCATA-
ACCAGTGGCTACTCCCA-39 and 59-TCCTTGGCAGCTTC-
TTCCTCTTCA-39), shank2 (59-GCGTGCATCCAAGAAATGC-
G-39 and 59-AGGTTCAGTAGACTCGAATGG-39), and GAPDH
(59-TCCCTCAAGATTGTCAGCAA-39 and 59-AGATCCACAA-
CGGATACATT-39) and 1.25 U of Taq DNA polymerase (Ta-
KaRa, Tokyo, Japan). Amplification was performed for a total of 25
to 35 cycles. To ensure the equal loading of mRNA in each lane,
GAPDH expression was measured.
Statistical Analysis
Statistical differences between groups were evaluated with the
Student’s unpaired t-test (two-tailed). Data were recorded as mean
6 SD. P values#0.05 were considered significant.
Results
Activation of TrkA Induced by VEGF in Retinoblastoma
Cells
First, we examined whether TrkA is expressed in retinoblastoma
cells. Compared to a colorectal cancer cell line, SW480 without
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expressed in both retinoblastoma cell lines of Y79 and SNUOT-
Rb1. (Figure 1A) Then, to determine whether VEGFR-2 and
TrKA, as a neurotrophin receptor are expressed in retinoblastoma
cells, the expression of VEGFR-2 and TrkB was measured in
retinoblastoma cell lines, Y79 and SNUOT-Rb1, by western blot
analysis. As demonstrated in figure 1B, TrkA as well as VEGFR-2
were expressed in high level in both retinoblastoma cell lines. As
depicted in our recent report [20], neurotrophin receptors
including TrkA and TrkB are differentially expressed in
retinoblastoma cells depending on cellular differentiation status.
In particular, TrkA expression is related to differentiation of
retinoblastoma cells. Therefore, it is interesting to note that the
addition of exogenous VEGF effectively induced phosphorylation
of TrkA in retinoblastoma cells. (Figure 1C).
Attenuation of Neurite Outgrowth by Bevacizumab in
Differentiated Retinoblastoma Cells
To investigate cytotoxic effect of bevacizumab on retinoblasto-
ma cells, cell viability was evaluated through MTT assay in various
concentrations of bevacizumab (0.1,10 mg/ml). As demonstrated
in figure 2A, the viability of retinoblastoma cells treated with
bevacizumab was not affected up to 2 mg/ml as our recent report
[17], whereas at a concentration of 10 mg/ml cellular viability of
retinoblastoma cells was significantly decreased. (*P,0.05) Next,
to investigate whether blockade of VEGF by bevacizumab could
inhibit differentiation of retinoblastoma cells, we measured neurite
length in differentiated retinoblastoma cells incubated with 0.1%
BSA. 1 mg/ml bevacizumab was applied to exclude inhibition of
neurite outgrowth from cytotoxicity findings for retinoblastoma
cells. As shown in figure 2B, neurite outgrowth significantly
increased with 0.1% BSA, which was, however, significantly
attenuated by bevacizumab treatment.
Inhibition of Neurofilament and Shank2 Expression by
Bevacizumab in Differentiated Retinoblastoma Cells
Given that shank 2 is expressed in the retina and colocalized
with neurofilament of a neuronal differentiation marker, which is
confirmed by its colocalization with neurofilament at the dendritic
region of the differentiated retinoblastoma cells [21], neurofila-
ment and shank2 expression were investigated to confirm whether
bevacizumab inhibits differentiation of retinoblastoma cells. We
used Western blotting to measure expression of neurofilament and
shank2 in differentiated retinoblastoma cells induced by 0.1%
BSA. As shown in figure 3A, up-regulation of neurofilament in
differentiated retinoblastoma cells was significantly inhibited by
1 mg/ml bevacizumab. Expectedly, shank2 expression was
significantly increased with treatment of 0.1% BSA, which was
nearly suppressed by bevacizumab treatment. (Figure 3B)
To confirm whether bevacizumab-induced shrinkage of neurite
outgrowth is related to loss of neurofilament and shank2
expression on outgrowing neurites, we performed immunocyto-
chemistry for neurofilament and shank2 in differentiated retino-
blastoma cells. As our recent report [21], neurofilament as well as
shank2 were diffusely expressed around the nucleus in undiffer-
entiated retinoblastoma cells, whereas they were prominently
expressed at the contacts of outgrowing neurites in differentiated
cells. (Figure 3C) However, neurite outgrowth was attenuated by
Figure 1. Activation of TrkA Induced by VEGF in Retinoblastoma Cells. (A) Proteins of human retinoblastoma cell lines, Y79 and SNUOT-Rb1
[22] as well as a human colorectal cancer cell lines, SW480 were resolved on 12% SDS-PAGE and western blot analysis was performed using anti-TrkA
antibody. b-actin was served as a loading control. Each figure is representative ones from three independent experiments. (B) Proteins of Y79 and
SNUOT-Rb1 cells were resolved on 12% SDS-PAGE and western blot analysis was performed using anti-VEGFR-2 and anti-TrkA antibody. b-actin was
served as a loading control. Each figure is representative ones from three independent experiments. (C) SNUOT-Rb1 cells were treated with 10 ng/ml
VEGF. TrkA and phospho-TrkA were detected by Western blot analysis. b-actin was served as a loading control. Each figure is representative ones
from three independent experiments.
doi:10.1371/journal.pone.0033456.g001
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expression of neurofilament and shank2 around the nucleus as
undifferentiated cells. (Figure 3C).
Next, Y79 cell line, another retinoblastoma cell line was used to
ensure that our provided results are not SNUOT-Rb1 specific
responses. In addition, human IgG was used as a non-specific
antibody to show that the response is not induced by non-specific
antibody. As shown in figure 3D, we measured neurite length in
differentiated retinoblastoma cells incubated with 0.1% BSA.
Neurite outgrowth significantly increased with 0.1% BSA, which
was, however, significantly attenuated by bevacizumab treatment.
(* P,0.05) However, human IgG treatment never affected to
neurite outgrowth induced by 0.1% BSA. (** P.0.05) In addition,
neurofilament expression in SNUOT-Rb 1 cells was significantly
increased with treatment of 0.1% BSA to induce the differenti-
ation of retinoblastoma cells, (* P,0.05) which was not affected
by human IgG treatment. (** P.0.05) However, the up-regulation
of neurofilament was completely inhibited by bevacizumab.
(* P,0.05) (Figure 3E).
Similar to SNUOT-Rb1, 0.1% BSA-induced expression of
neurofilament in Y79 retinoblastoma cells (* P,0.05) was not
suppressed by human IgG treatment, (** P.0.05) which was
significantly inhibited by bevacizumab. (* P,0.05) (Figure 3F)
Furthermore, shank2 expression in Y79 cells was increased with
treatment of 0.1% BSA, (* P,0.05) which was not affected by
human IgG treatment. (** P.0.05) However, its up-regulation was
effectively inhibited by bevacizumab. (* P,0.05) (Figure 3G).
Bevacizumab-induced Inhibition of Differentiation of
Retinoblastoma Cells through Blockade of ERK 1/2
Activation
Base on our reports that differentiation of retinoblastoma cells
would be mediated by ERK 1/2 activation [23,25], we addressed
whether ERK 1/2 activation is changed in differentiated retinoblas-
toma cells by 1 mg/ml bevacizumab. As demonstrated in figure 4,
phospho-ERK 1/2 was significantly increased in differentiated
retinoblastoma cells, which was completely inhibited by bevacizumab
treatment. However, there was no change in expression of Akt and
phospho-Akt in differentiated retinoblastoma cell with bevacizumab
treatment. (Figure 4).
Discussion
Herein, we clearly demonstrated that bevacizumab treatment
could inhibit differentiation of retinoblastoma cells without any
change in cellular viability, which would be mediated via blockade
of ERK 1/2 activation.
VEGF is considered as the most critical regulator of
angiogenesis in physiological as well as pathological conditions,
which is evidently mediated by the high-affinity cell surface
Figure 2. Attenuation of Neurite Outgrowth by Bevacizumab in Differentiated Retinoblastoma Cells. (A) SNUOT-Rb1 cells were treated
with 0.1 to 10 mg/ml bevacizumab. Cell viability was measured by MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay.
Quantitative analysis was performed by measuring viable cells relative to the controls. Each value represents means 6 SE from three independent
experiments (*P,0.05). (B) SNUOT-Rb1 cells were treated with either 0.1% BSA or 1 mg/ml bevacizumab. Neurite length in differentiated
retinoblastoma cells was measured by manual tracing of neurite outgrowth in each cell. The figures that appear here were selected as representative
of data from three independent experiments. Quantitative analysis was performed using average length from total neurites measured. Each value
represents means 6 SE from three independent experiments (*P,0.05). Scale bar, 20 mm. BSA, bovine serum albumin.
doi:10.1371/journal.pone.0033456.g002
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bind to its receptors with high affinity, essential angiogenic pro-
cesses are activated by VEGFR-2 transmission whereas VEGFR-1
indirectly modulates VEGFR-2 responses by decoying VEGF
[26]. Accordingly, disturbance in VEGF-VEGFR-2 pathway
causes severe vascular defects, which could be therapeutically
applied to tumor angiogenesis and vaso-proliferative retinopathies
[2,25]. Therefore, regardless of empirical evidence in clinics, anti-
VEGF treatment using bevacizumab has been extensively applied
in variable vaso-proliferative retinopathies [12–14]. Some clinical
reports have demonstrated that intravitreal bevacizumab would be
most effective against angiogenic and edematous ocular diseases
[27,28]. However, because VEGF could play as a neurotrophic
and neuroprotective factor in nervous system as well as critical
roles in vessels, VEGF inhibition could lead to serious neuroretinal
damages [3–7]. In the retina, VEGF and VEGFR-2 are expressed
throughout most of neural retina including neurons, astrocytes,
pericytes and Mu ¨ller cells, which suggest that VEGF would be
critical for more than its vascular roles [29]. As a result, systemic
VEGF neutralization induces retinal degeneration through
inhibition of VEGF-mediated neuroprotective effect on retinal
neurons [29]. In contrast, a recent report provides that even long-
term blockade of VEGF signaling could be applied in the retina
without any toxicity to retinal cells [30]. Given opposite
conclusions at controversy, it should be carefully investigated
whether VEGF antagonism affect to retinal toxicity.
Interestingly, we found out that TrkA, a neurotrophin receptor,
expressed on retinoblastoma cells can be phosphorylated by
addition of VEGF, which is supported by a report that endothelial
cell-derived VEGF enhances adult neurogenesis in a neurotrophin-
dependent manner [31]. Considering our recent report that TrkA is
involved in differentiation of retinoblastoma cells [20], This VEGF-
induced activation of TrkA strongly encourage to investigate the
effect of VEGF blockade on differentiation of retinoblastoma cells.
Expectedly, VEGF neutralization using bevacizumab could lead to
inhibition of differentiation of retinoblastoma cells without any
affection to cellular viability. Bevacizumab treatment significantly
attenuated neurite outgrowths in differentiated retinoblastoma cells.
In neuronal differentiation, neurite outgrowth followed by axonal
elongation and dendritic arborization is a fundamental morpho-
logical characteristic, which could be accompanied by neurofila-
ment in axonal compartment and shank2, as a synaptic protein in
dendritic area [20]. With treatment of bevacizumab, attenuation of
neurite outgrowth in differentiated retinoblastoma cells was
followed by inhibition of up-regulation of neurofilament and shank
expression.
Although VEGF and nerve growth factor (NGF) as a neurotro-
phin were originally discovered to be specific for endothelial and
neuronal cells, respectively, recent insights indicate that VEGF and
NGF directly exert cross talk between nervous and vascular system
[3,4]. In detail, stimulation by VEGF and NGF can activate
common intracellular signaling pathways of phosphoinositide 3-
kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/
ERK pathway [6,7]. We clearly showed that VEGF neutralization
was significantly inhibited differentiation of retinoblastoma cells via
blockade of ERK pathway, which is strongly supported by our
recent reports [20,23,25].
In conclusion, our data suggests that VEGF inhibition could
affect to differentiation of retinoblastoma cells though no cellular
toxicity. Based on that the differentiated retinoblastoma cells are
Figure 3. Inhibition of Neurofilament and Shank2 Expression by Bevacizumab in Differentiated Retinoblastoma Cells. (A, B) SNUOT-
Rb1 cells were treated with 0.1% BSA or 1 mg/ml bevacizumab. Neurofilament (A) and shank2 (B) were detected by Western blot analysis. b-actin was
served as a loading control. Each figure is representative ones from three independent experiments. Quantitative analysis was performed by
measuring protein expression relative to the controls. Each value represents means 6 SE from three independent experiments (*P,0.05). BSA, bovine
serum albumin. (C) SNUOT-Rb1 cells were treated with 0.1% BSA or 1 mg/ml bevacizumab. Neuronal differentiation was addressed by the
morphological changes of neurite extensions. Immunocytochemistry for neurofilament (green) and shank2 (red) was performed, and nuclei were
labeled with DAPI (blue). Each figure is representative ones from three independent experiments. Scale bar, 20 mm. DAPI, 49, 6-diamidino-2-
phenolindole. (D) SNUOT-Rb1 cells were treated with 0.1% BSA, 1 mg/ml human IgG, or 1 mg/ml bevacizumab. Neurite length in differentiated
retinoblastoma cells was measured by manual tracing of neurite outgrowth in each cell. Quantitative analysis was performed using average length
from total neurites measured. Each value represents means 6 SE from three independent experiments (*P,0.05, **P.0.05). (E, F, G) Retinoblastoma
cells of SNUOT-Rb1 (E) and Y79 (F, G) were treated with either 0.1% BSA or 1 mg/ml human IgG. Total mRNA was isolated from retinoblastoma cells,
and reverse transcriptase-polymerase chain reaction was performed with specific primers for neurofilament or shank2. GAPDH was served as an
internal control. Each figure is representative ones from three independent experiments. Quantitative analysis was performed by measuring mRNA
expression relative to the control. Each value represents means 6 SE from three independent experiments (*P,0.05, **P.0.05).
doi:10.1371/journal.pone.0033456.g003
Figure 4. Bevacizumab-induced Inhibition of Differentiation of
Retinoblastoma Cells through Blockade of ERK 1/2 Activation.
SNUOT-Rb1 cells were treated with 0.1% BSA or 1 mg/ml bevacizumab.
ERK 1/2, phospho-ERK 1/2, Akt, and phospho-Akt were detected by
Western blot analysis. b-actin was served as a loading control. Each
figure is representative ones from three independent experiments.
Quantitative analysis was performed by measuring protein expression
relative to the controls. Each value represents means 6 SE from three
independent experiments (*P,0.05, **P.0.05). BSA, bovine serum
albumin.
doi:10.1371/journal.pone.0033456.g004
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therapies would affect to the maintenance or function of
photoreceptors in mature retina, which is supported by a recent
report that the neutralization of endogenous VEGF leads to
unexpected neural toxicity [29]. Therefore, regardless of recent
reports to demonstrate few clinically relevant ocular side effect
[27,28], pros and cons of anti-VEGF treatment should be carefully
scrutinized.
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